Published in Biomol Ther (Seoul) on November 01, 2015
Phase 3 Frontline Therapy Trial in Patients With Advanced Classical Hodgkin Lymphoma | NCT01712490
SAR3419 in Acute Lymphoblastic Leukemia (MYRALL) | NCT01440179
Eradication of Tumors through Simultaneous Ablation of CD276/B7-H3-Positive Tumor Cells and Tumor Vasculature. Cancer Cell (2017) 1.39
Marked enhancement of lysosomal targeting and efficacy of ErbB2-targeted drug delivery by HSP90 inhibition. Oncotarget (2016) 0.76
Linkers Having a Crucial Role in Antibody-Drug Conjugates. Int J Mol Sci (2016) 0.75
Antibody-drug conjugates and other nanomedicines: the frontier of gynaecological cancer treatment. Interface Focus (2016) 0.75
Quantitative characterization of in vitro bystander effect of antibody-drug conjugates. J Pharmacokinet Pharmacodyn (2016) 0.75
Multivalent peptidic linker enables identification of preferred sites of conjugation for a potent thialanstatin antibody drug conjugate. PLoS One (2017) 0.75
A phase II study of antibody-drug conjugate, TAK-264 (MLN0264) in previously treated patients with advanced or metastatic pancreatic adenocarcinoma expressing guanylyl cyclase C. Invest New Drugs (2017) 0.75
Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin's lymphoma. J Clin Oncol (2012) 6.78
Specific inhibition of nuclear RNA polymerase II by alpha-amanitin. Science (1970) 6.39
Site-specific conjugation of a cytotoxic drug to an antibody improves the therapeutic index. Nat Biotechnol (2008) 5.54
Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate. Cancer Res (2008) 5.34
Anti-inflammatory activity of human IgG4 antibodies by dynamic Fab arm exchange. Science (2007) 4.52
Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: results of a phase II study. J Clin Oncol (2012) 4.41
Genetic incorporation of unnatural amino acids into proteins in mammalian cells. Nat Methods (2007) 3.45
Drug delivery strategy utilizing conjugation via reversible disulfide linkages: role and site of cellular reducing activities. Adv Drug Deliv Rev (2003) 3.25
An enhanced system for unnatural amino acid mutagenesis in E. coli. J Mol Biol (2009) 3.20
Effects of drug loading on the antitumor activity of a monoclonal antibody drug conjugate. Clin Cancer Res (2004) 3.16
Addition of the keto functional group to the genetic code of Escherichia coli. Proc Natl Acad Sci U S A (2002) 2.84
Inotuzumab ozogamicin, an anti-CD22-calecheamicin conjugate, for refractory and relapsed acute lymphocytic leukaemia: a phase 2 study. Lancet Oncol (2012) 2.76
Development of potent monoclonal antibody auristatin conjugates for cancer therapy. Nat Biotechnol (2003) 2.75
Introducing genetically encoded aldehydes into proteins. Nat Chem Biol (2007) 2.65
Phase I clinical trial using escalating single-dose infusion of chimeric anti-CD20 monoclonal antibody (IDEC-C2B8) in patients with recurrent B-cell lymphoma. Blood (1994) 2.48
Conjugation site modulates the in vivo stability and therapeutic activity of antibody-drug conjugates. Nat Biotechnol (2012) 2.43
Approval summary: gemtuzumab ozogamicin in relapsed acute myeloid leukemia. Clin Cancer Res (2001) 2.35
Phase III trial of consolidation therapy with yttrium-90-ibritumomab tiuxetan compared with no additional therapy after first remission in advanced follicular lymphoma. J Clin Oncol (2008) 2.32
Unraveling the role of proteases in cancer. Clin Chim Acta (2000) 2.27
SGN-CD33A: a novel CD33-targeting antibody-drug conjugate using a pyrrolobenzodiazepine dimer is active in models of drug-resistant AML. Blood (2013) 2.26
Proteolytic networks in cancer. Trends Cell Biol (2011) 2.10
Final report of the efficacy and safety of gemtuzumab ozogamicin (Mylotarg) in patients with CD33-positive acute myeloid leukemia in first recurrence. Cancer (2005) 2.08
Epratuzumab, a humanized anti-CD22 antibody, in aggressive non-Hodgkin's lymphoma: phase I/II clinical trial results. Clin Cancer Res (2004) 2.00
Synthesis of site-specific antibody-drug conjugates using unnatural amino acids. Proc Natl Acad Sci U S A (2012) 1.99
HER2-amplified breast cancer: mechanisms of trastuzumab resistance and novel targeted therapies. Expert Rev Anticancer Ther (2011) 1.92
Location matters: site of conjugation modulates stability and pharmacokinetics of antibody drug conjugates. Chem Biol (2013) 1.82
Intracellular activation of SGN-35, a potent anti-CD30 antibody-drug conjugate. Clin Cancer Res (2010) 1.81
A phase I clinical trial with monoclonal antibody ch806 targeting transitional state and mutant epidermal growth factor receptors. Proc Natl Acad Sci U S A (2007) 1.79
Enhanced activity of monomethylauristatin F through monoclonal antibody delivery: effects of linker technology on efficacy and toxicity. Bioconjug Chem (2006) 1.68
Antibody-maytansinoid conjugates are activated in targeted cancer cells by lysosomal degradation and linker-dependent intracellular processing. Cancer Res (2006) 1.67
Structure-based design of beta 1,4-galactosyltransferase I (beta 4Gal-T1) with equally efficient N-acetylgalactosaminyltransferase activity: point mutation broadens beta 4Gal-T1 donor specificity. J Biol Chem (2002) 1.66
Polymeric anticancer drugs with pH-controlled activation. Adv Drug Deliv Rev (2004) 1.65
Engineered thio-trastuzumab-DM1 conjugate with an improved therapeutic index to target human epidermal growth factor receptor 2-positive breast cancer. Clin Cancer Res (2010) 1.63
Association with membrane protrusions makes ErbB2 an internalization-resistant receptor. Mol Biol Cell (2004) 1.63
Contribution of linker stability to the activities of anticancer immunoconjugates. Bioconjug Chem (2008) 1.59
Brentuximab Vedotin (SGN-35). Clin Cancer Res (2011) 1.56
CC-1065 and the duocarmycins: unraveling the keys to a new class of naturally derived DNA alkylating agents. Proc Natl Acad Sci U S A (1995) 1.51
Cure of xenografted human carcinomas by BR96-doxorubicin immunoconjugates. Science (1993) 1.47
Gene family encoding the major toxins of lethal Amanita mushrooms. Proc Natl Acad Sci U S A (2007) 1.45
Recent developments in the maytansinoid antitumor agents. Chem Pharm Bull (Tokyo) (2004) 1.45
A Phase II study of SGN-30 (anti-CD30 mAb) in Hodgkin lymphoma or systemic anaplastic large cell lymphoma. Br J Haematol (2009) 1.44
Antibody-drug conjugates for the treatment of non-Hodgkin's lymphoma: target and linker-drug selection. Cancer Res (2009) 1.41
Randomized phase II study of BR96-doxorubicin conjugate in patients with metastatic breast cancer. J Clin Oncol (1999) 1.41
Site-specific chemical protein conjugation using genetically encoded aldehyde tags. Nat Protoc (2012) 1.40
In vivo drug-linker stability of an anti-CD30 dipeptide-linked auristatin immunoconjugate. Clin Cancer Res (2005) 1.38
Phase I/II study of an anti-CD30 monoclonal antibody (MDX-060) in Hodgkin's lymphoma and anaplastic large-cell lymphoma. J Clin Oncol (2007) 1.38
Safety, pharmacokinetics, and preliminary clinical activity of inotuzumab ozogamicin, a novel immunoconjugate for the treatment of B-cell non-Hodgkin's lymphoma: results of a phase I study. J Clin Oncol (2010) 1.38
Phase I trial of the anti-Lewis Y drug immunoconjugate BR96-doxorubicin in patients with lewis Y-expressing epithelial tumors. J Clin Oncol (2000) 1.34
Antimitotic activity of the potent tumor inhibitor maytansine. Science (1975) 1.33
Antibody-drug conjugates of calicheamicin derivative: gemtuzumab ozogamicin and inotuzumab ozogamicin. Clin Cancer Res (2011) 1.32
Site-specific and stoichiometric modification of antibodies by bacterial transglutaminase. Angew Chem Int Ed Engl (2010) 1.31
Engineered antibody-drug conjugates with defined sites and stoichiometries of drug attachment. Protein Eng Des Sel (2006) 1.29
Selective destruction of target cells by diphtheria toxin conjugated to antibody directed against antigens on the cells. Science (1970) 1.29
Mylotarg (gemtuzumab ozogamicin) therapy is associated with hepatic venoocclusive disease in patients who have not received stem cell transplantation. Cancer (2001) 1.28
Antibody-radionuclide conjugates for cancer therapy: historical considerations and new trends. Clin Cancer Res (2011) 1.27
Molecularly defined antibody conjugation through a selenocysteine interface. Biochemistry (2009) 1.23
Anti-CD74 antibody-doxorubicin conjugate, IMMU-110, in a human multiple myeloma xenograft and in monkeys. Clin Cancer Res (2005) 1.22
Therapeutic potential of CD22-specific antibody-targeted chemotherapy using inotuzumab ozogamicin (CMC-544) for the treatment of acute lymphoblastic leukemia. Leukemia (2007) 1.21
Cantuzumab mertansine, a maytansinoid immunoconjugate directed to the CanAg antigen: a phase I, pharmacokinetic, and biologic correlative study. J Clin Oncol (2003) 1.21
Therapeutic potential of an anti-CD79b antibody-drug conjugate, anti-CD79b-vc-MMAE, for the treatment of non-Hodgkin lymphoma. Blood (2009) 1.19
Maytansinoid-antibody conjugates induce mitotic arrest by suppressing microtubule dynamic instability. Mol Cancer Ther (2010) 1.19
Rapid identification of reactive cysteine residues for site-specific labeling of antibody-Fabs. J Immunol Methods (2008) 1.11
Direct identification of nonreducing GlcNAc residues on N-glycans of glycoproteins using a novel chemoenzymatic method. Bioconjug Chem (2007) 1.11
Potent anticarcinoma activity of the humanized anti-CD70 antibody h1F6 conjugated to the tubulin inhibitor auristatin via an uncleavable linker. Clin Cancer Res (2008) 1.11
Site specific conjugation of fluoroprobes to the remodeled Fc N-glycans of monoclonal antibodies using mutant glycosyltransferases: application for cell surface antigen detection. Bioconjug Chem (2009) 1.08
Therapeutic potential of amanitin-conjugated anti-epithelial cell adhesion molecule monoclonal antibody against pancreatic carcinoma. J Natl Cancer Inst (2012) 1.06
CD30: an important new target in hematologic malignancies. Leuk Lymphoma (2011) 1.05
Calicheamicins, a novel family of antitumor antibiotics. 3. Isolation, purification and characterization of calicheamicins beta 1Br, gamma 1Br, alpha 2I, alpha 3I, beta 1I, gamma 1I and delta 1I. J Antibiot (Tokyo) (1989) 1.05
High CD21 expression inhibits internalization of anti-CD19 antibodies and cytotoxicity of an anti-CD19-drug conjugate. Br J Haematol (2007) 1.03
Synthesis and evaluation of hydrophilic linkers for antibody-maytansinoid conjugates. J Med Chem (2011) 1.01
Disulfide-linked antibody-maytansinoid conjugates: optimization of in vivo activity by varying the steric hindrance at carbon atoms adjacent to the disulfide linkage. Bioconjug Chem (2011) 1.01
World Antibody Drug Conjugate Summit Europe: February 21-23, 2011; Frankfurt, Germany. MAbs (2011) 1.00
Main drug-metabolizing enzyme systems in human breast tumors and peritumoral tissues. Cancer Res (1993) 0.99
Engineered anti-CD70 antibody-drug conjugate with increased therapeutic index. Mol Cancer Ther (2008) 0.99
An anti-CD33 antibody-calicheamicin conjugate for treatment of acute myeloid leukemia. Choice of linker. Bioconjug Chem (2002) 0.96
Anti-CD30 diabody-drug conjugates with potent antitumor activity. Mol Cancer Ther (2008) 0.95
Development and properties of beta-glucuronide linkers for monoclonal antibody-drug conjugates. Bioconjug Chem (2006) 0.94
Design, synthesis, and in vitro evaluation of dipeptide-based antibody minor groove binder conjugates. J Med Chem (2005) 0.93
Shedding of the soluble form of CD30 from the Hodgkin-analogous cell line L540 is strongly inhibited by a new CD30-specific antibody (Ki-4). Int J Cancer (1995) 0.92
Doxorubicin conjugated with a monoclonal antibody directed to a human melanoma-associated proteoglycan suppresses the growth of established tumor xenografts in nude mice. Proc Natl Acad Sci U S A (1988) 0.91
Tumor Cell Expression of CD59 Is Associated With Resistance to CD20 Serotherapy in Patients With B-Cell Malignancies. J Immunother (1991) (2001) 0.91
Curative properties of noninternalizing antibody-drug conjugates based on maytansinoids. Cancer Res (2014) 0.90
Monoclonal antibody KS1/4-methotrexate immunoconjugate studies in non-small cell lung carcinoma. Am J Respir Crit Care Med (1994) 0.87
Antibody-guided radiation therapy of cancer. Cancer Metastasis Rev (2005) 0.85
Minor groove binder antibody conjugates employing a water soluble beta-glucuronide linker. Bioorg Med Chem Lett (2007) 0.82
The human immune response to KS1/4-desacetylvinblastine (LY256787) and KS1/4-desacetylvinblastine hydrazide (LY203728) in single and multiple dose clinical studies. Cancer Res (1991) 0.82
Enhancement of tumor uptake and therapeutic efficacy of EGFR-targeted antibody cetuximab and antibody-drug conjugates by cholesterol sequestration. Int J Cancer (2014) 0.81
Structural and conformational features relevant to the anti-tumor activity of calicheamicin γ 1I. Chirality (2011) 0.80
Structure-activity studies with chiral isomers and with segments of the antimitotic marine peptide dolastatin 10. Biochem Pharmacol (1990) 0.80
Emerging immunotherapies targeting CD30 in Hodgkin's lymphoma. Biochem Pharmacol (2010) 0.80
Rituximab: converging mechanisms of action in non-Hodgkin's lymphoma? Clin Cancer Res (2003) 0.78
Drug update: trastuzumab: anti-HER2 antibody for treatment of metastatic breast cancer. Cancer Pract (2000) 0.78
Phase II evaluation of maytansine (NSC 153858) in advanced cancer. A Southeastern Cancer Study Group trial. Am J Clin Oncol (1985) 0.77
Inotuzumab ozogamicin in the treatment of acute lymphoblastic leukemia. Front Biosci (Elite Ed) (2014) 0.76